Actuate Therapeutics
ACTU
38 hedge funds and large institutions have $68.5M invested in Actuate Therapeutics in 2025 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 12 increasing their positions, 2 reducing their positions, and 8 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 2
163% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 8
52% more funds holding
Funds holding: 25 → 38 (+13)
3.91% more ownership
Funds ownership: 53.26% → 57.17% (+3.9%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less capital invested
Capital invested by funds: $70.4M → $68.5M (-$1.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.15M |
| 2 |
BlackRock
New York
|
+$1.64M |
| 3 |
VC
Voss Capital
Houston,
Texas
|
+$1.26M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$739K |
| 5 |
BCM
BIOS Capital Management
Fort Worth,
Texas
|
+$624K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$322K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$160K |
| 3 |
Goldman Sachs
New York
|
-$151K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$150K |
| 5 |
Mercer Global Advisors
Denver,
Colorado
|
-$111K |
ACTU Hedge Fund Activity: Q2 2025 in Review
38 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Actuate Therapeutics (ACTU) for Q2 2025, worth a combined $68.5M — down 2.7% from $70.4M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ACTU positions and 8 closed out — a net gain of 13 holders — while 12 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.15M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $322K sold.
- 38 institutional investors held Actuate Therapeutics (ACTU) as of Q2 2025, up from 25 in Q1 2025.
- Funds reported $68.5M of Actuate Therapeutics stock for Q2 2025, down 2.7% quarter-over-quarter.
- 21 funds opened new Actuate Therapeutics positions in Q2 2025 and 8 closed out, a net change of +13 holders.
- The largest Actuate Therapeutics buyer in Q2 2025 was Vanguard Group, an estimated $2.15M added.
- The largest Actuate Therapeutics seller in Q2 2025 was Susquehanna International Group, an estimated $322K sold.
Based on aggregated 13F filings for Q2 2025.